EP: 1.Overview of Clear Cell RCC

EP: 2.Receiving a Diagnosis of Metastatic RCC: A Patient’s Journey

Now Viewing

EP: 3.Patient Education Resources for RCC

EP: 4.First-Line Treatment Options for Metastatic Clear Cell RCC

EP: 5.A Patient’s Perspective on Choosing Systemic Therapy for Metastatic RCC

EP: 6.Lenvatinib + Pembrolizumab for the Treatment of Metastatic Clear Cell RCC

EP: 7.Factors for Consideration in RCC Treatment Decision-Making

EP: 8.Role of Nurses in the Multidisciplinary Management of RCC

EP: 9.Adverse Events Associated with IO-TKI Therapies in Metastatic Clear Cell RCC

EP: 10.Patient Experience with Systemic Therapy-Related Toxicities in Metastatic RCC

EP: 11.Quality-of-Life with Systemic Therapies in Metastatic Clear Cell RCC

EP: 12.The Importance of Patients Advocating for Themselves During Their RCC Journey

EP: 13.Unmet Needs and Future Perspectives in the Treatment of RCC

Chung-Han Lee, MD: Mr Lewis, can you talk a little about the resources that KidneyCAN can help patients with?

Bryan Lewis: Yes. Thank you, Dr Lee. KidneyCAN, historically, has focused on advocacy in Washington D.C. and trying to raise awareness that way. But we also realize that awareness in general can lead to more advocacy in a growing grassroots army. If we do that advocacy, that leads to funding. If we get the funding and more research can be funded, then we hope to accelerate cures that way. That’s our circular approach.

But we realized when we were doing so much advocacy that people were bouncing off the KidneyCAN website because we didn’t have a lot of educational resources. We embarked on creating a patient resource center. It’s recently underway, so I can’t claim that it’s finished. However, we realize we’re not going to recreate the wheel. There are a lot of reliable, valid sources out there. We’ve tried to bring it all together in a library-type of approach. We have big buckets of information around diagnosis, building a care team, clinical trials, and living well with cancer. We’re trying to start there and then dive down. We utilize the NCCN [National Comprehensive Cancer Network] Guidelines. They also have our patient’s version of the guidelines, which is very readable, understandable, and comprehensive.

There are a lot of other sources, including Smart Patients, an online forum that Meryl talked about. We have a town hall series throughout the year where we have a research review of the previous year and talk with experts in the field about where we’re headed. We talk to other patients around the country, asking questions. We have one coming up on selection, immunotherapy, and shared decision-making. We’re trying to build that portfolio of education and awareness because we found that people were bouncing off our website because they were probably in the early [stages of] diagnosis or new to the kidney cancer space. We were a little more downfield with the advocacy. We’re building that out. Hopefully, those resources will continue to grab the best [information] from around the globe.

I have to put a plug in for the International Kidney Cancer Coalition, at ikcc.org. They have a wonderful library of resources. You can download and print decision aids and ways to talk to your doctor and ask questions and follow up. It’s another great resource. There are a lot out there.

Chung-Han Lee, MD: Yes. That’s fantastic that you’re able to put that together. For a patient, the ability to have a well-curated source of information is invaluable. The hardest thing for a patient is to type kidney cancer into their search engine of choice and then get this huge list of random links and to try to parse through that to decide what to do. The fact that your organization is able to put together this type of list is very appreciated by the patient community.

Transcript edited for clarity.